Research News
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.
Jason Meyer, PhD, is a BrightFocus Foundation success story and a pioneer in the effort to regenerate eye tissue that is damaged by glaucoma.
New BrightFocus-funded research explores how a protein called tau, critical to Alzheimer’s, turns from normal to a diseased state. This discovery presents a new target to potentially prevent or treat Alzheimer's disease.
Eye-brain research is revealing that the APOE4 mutation has a much different impact in glaucoma than in Alzheimer’s, a discovery that may lead to a new glaucoma treatment.
A team including two BrightFocus grantees has successfully transplanted a patch of retinal tissue into a patient with geographic atrophy. This experimental therapy was part of an NIH clinical trial and marks the first time in the U.S. that stem cells derived from a patient’s own tissue have been used to replace eye cells.
A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.
Donald Weaver’s $1 million BrightFocus Centennial grant helped lead to his new exploration of Alzheimer’s roots, which he and colleagues have proposed may lie with an out-of-control autoimmune reaction.
